PubMed Health⌕ Search

Biomedical subjects

C F Curran

Publications and source records attributed to C F Curran.

14 recordsLinked to original sources
PubMed1990

Extravasation of doxorubicin from vascular access devices.

An assessment was made of 36 extravasations of Adriamycin (doxorubicin) in which vascular access devices had been used. Of these, 25 (69%) were sufficiently severe to warrant removal of the device. Physical manifestations were frequently of delayed onset. Edema and/or erythema often involved extensive areas around the catheter or access device and in several cases were accompanied by pain, discomfort or paresthesia. In 20 patients (59%), spontaneous resolution without ulceration occurred in spite of occasional extravasation of large amounts of doxorubicin. Most extravasations were caused by a limited number of technical errors and equipment problems. These were equally divided by site into injection port extravasations and catheter-related extravasations (18 patients each). The two most frequent causes were needle and catheter tip dislodgements. Procedures are suggested for minimizing the opportunities for extravasation of doxorubicin administered through vascular access devices.

Catheterization↗
PubMed1989

Ocular adverse reactions associated with adriamycin (doxorubicin).

To assess the ocular safety of doxorubicin, we reviewed doxorubicin-associated ocular adverse reactions reported to Adria Laboratories or published in the clinical literature. Conjunctivitis was the most frequently reported reaction. Periorbital edema was reported in two patients, and lacrimation was reported in a published study. Blepharospasm, keratitis, and decreased visual acuity were reported once each in patients treated with combination chemotherapeutic regimens containing doxorubicin. These reactions usually resolved rapidly on discontinuation of the drug. Conjunctivitis frequently followed accidental ocular exposure to doxorubicin. All but a few of these reactions cleared within 24 hours of exposure. The infrequent nature and usually rapid resolution of these ocular adverse reactions suggest that when ocular toxicities occur in patients undergoing doxorubicin-containing chemotherapy, the cautious reintroduction of doxorubicin, if further antineoplastic therapy is indicated, should be considered.

Aged↗
PubMed1989

Accidental acute exposure to doxorubicin.

Accidental ocular exposure to doxorubicin was followed by no reaction or rapidly resolving conjunctivitis in 13 of 15 cases (87%). In the two remaining cases, persistent photophobia and chronic inflammation were reported. Of 28 accidental exposures to sites other than the eyes, no reactions or rapidly resolving local reactions were reported in 24 cases (86%). Nurses are at particular risk for accidental exposure to doxorubicin and accounted for 20 of the 43 reported exposures (47%).

Conjunctivitis↗
PubMedDate not supplied

Doxorubicin-associated flare reactions.

An analysis was made of 539 cases of venous flare reactions associated with the administration of doxorubicin. These reactions always were nondebilitating and generally were transient with complete resolution occurring within 45 minutes of onset in 462 patients (86%). Local urticaria occurred in 133 patients (25%), and 35 patients (6%) reported either vein pain or a stinging sensation. In 20 cases (4%), erythema in the region immediately surrounding the infusion site accompanied the primary manifestation of erythema along the course of the vein proximal to the infusion site. The incidence of initial flare reactions peaked in the autumn months. These reactions frequently occurred at clinical sites in sporadic clusters. Clinical features are described that differentiate flare reactions from early extravasations of doxorubicin. Procedures for minimizing the possibility of the occurrence or reappearance of flare reactions are suggested.

Adolescent↗